116 related articles for article (PubMed ID: 29107335)
1. Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment.
Eriksson M; Hååg P; Brzozowska B; Lipka M; Lisowska H; Lewensohn R; Wojcik A; Viktorsson K; Lundholm L
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):174-187. PubMed ID: 29107335
[TBL] [Abstract][Full Text] [Related]
2. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K
Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.
Barr MP; Gray SG; Hoffmann AC; Hilger RA; Thomale J; O'Flaherty JD; Fennell DA; Richard D; O'Leary JJ; O'Byrne KJ
PLoS One; 2013; 8(1):e54193. PubMed ID: 23349823
[TBL] [Abstract][Full Text] [Related]
4. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
Lundholm L; Hååg P; Juntti T; Lewensohn R; Viktorsson K
Int J Radiat Biol; 2014 Aug; 90(8):718-26. PubMed ID: 24646078
[TBL] [Abstract][Full Text] [Related]
5. Small nucleolar RNA signatures of lung tumor-initiating cells.
Mannoor K; Shen J; Liao J; Liu Z; Jiang F
Mol Cancer; 2014 May; 13():104. PubMed ID: 24886050
[TBL] [Abstract][Full Text] [Related]
6. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
8. Role of chromatin structure modulation by the histone deacetylase inhibitor trichostatin A on the radio-sensitivity of ataxia telangiectasia.
Meschini R; Morucci E; Berni A; Lopez-Martinez W; Palitti F
Mutat Res; 2015 Jul; 777():52-9. PubMed ID: 25942615
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer.
Jeon JH; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Cancer Lett; 2008 Dec; 272(2):232-41. PubMed ID: 18762365
[TBL] [Abstract][Full Text] [Related]
11. Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma.
Li R; Huang J; Ma M; Lou Y; Zhang Y; Wu L; Chang DW; Zhao P; Dong Q; Wu X; Han B
Oncotarget; 2016 Oct; 7(42):68360-68370. PubMed ID: 27588392
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional cell growth confers radioresistance by chromatin density modification.
Storch K; Eke I; Borgmann K; Krause M; Richter C; Becker K; Schröck E; Cordes N
Cancer Res; 2010 May; 70(10):3925-34. PubMed ID: 20442295
[TBL] [Abstract][Full Text] [Related]
14. Modulation of chromatin conformation by the histone deacetylase inhibitor trichostatin A promotes the removal of radiation-induced lesions in ataxia telangiectasia cell lines.
Egidi A; Filippi S; Manganello F; Lopez-Martinez W; Meschini R
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt A):109-116. PubMed ID: 30389153
[TBL] [Abstract][Full Text] [Related]
15. Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line.
Zhao C; Setrerrahmane S; Xu H
Oncol Rep; 2015 Oct; 34(4):2126-32. PubMed ID: 26239272
[TBL] [Abstract][Full Text] [Related]
16. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
[TBL] [Abstract][Full Text] [Related]
17. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2.
Huang Z; Shen G; Gao J
Clin Transl Oncol; 2021 Sep; 23(9):1743-1751. PubMed ID: 33721187
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.
Zhao S; Yu N; Wang H; Wan Z; Diao C; Chen Y; Liu T; Yang Y; Gao F; Bai C; Cao K; Cai J
J Gene Med; 2023 Dec; 25(12):e3565. PubMed ID: 37460393
[TBL] [Abstract][Full Text] [Related]
19. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Gavrilov V; Lavrenkov K; Ariad S; Shany S
Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
[TBL] [Abstract][Full Text] [Related]
20. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
